MagAssist Medical Achieves Fourth Consecutive Inclusion in Future Healthcare 100 Strong List Amid IPO Filing

On May 9-10, 2025, the Future Healthcare 100 Exhibition, themed "THE NOW Tipping Point," grandly opened at the Suzhou International Expo Center. At this era-defining event focusing on the "ice and fire collision" within the healthcare industry, magAssist once again claimed the honor of being listed in the [Top 100 Innovative Devices and Intelligent Manufacturing], achieving its fourth consecutive appearance on the list, thanks to its continuously breakthrough innovation capabilities.

As an authoritative innovation benchmark in the medical and healthcare field, the main list of the Future Healthcare 100 is based on the VB100 Value Assessment System. After undergoing rigorous processes such as company applications, third-party reviews, and expert final evaluations, leading companies in four key areas are selected based on 17 core indicators including valuation size, technology transfer, and resource synergy. This consecutive win reaffirms magAssist's continued leadership in the high-end medical device sector.

In the dual melody of capital cooling and innovation bursting, magAssist has delivered an extremely valuable annual report: its self-developed fully magnetically suspended external ventricular assist device, MoyoAssist®, not only obtained the National Medical Products Administration's innovative medical device certification but also successfully achieved technological transformation and launched in the market, ending the long-term import monopoly in this field; safeguarding the new generation of extracorporeal membrane oxygenation system ECMO - BreathMo for the Hangzhou Asian Games.®, relying on 5G mobile emergency vehicles to build a lifeline, simultaneously won the Jiangsu Province Major Scientific and Technological Achievement Transformation Project; the interventional ventricular assist system NyokAssist® Approved by the National Medical Products Administration (NMPA) as an innovative medical device, granted access to the "Green Channel," becoming the first artificial heart product to simultaneously receive the FDA's "Breakthrough Device" designation and the NMPA's "Innovative Medical Device" recognition! To date, NyokAssist® Clinical Trial Enrollment Exceeds 100 Cases!

Notably, the company has built a three-dimensional solution covering the entire course of heart failure, setting industry benchmarks in non-endpoint treatment technology, breadth of indication coverage, and multi-scenario application dimensions. Facing a critical breakthrough period in the global medical and health industry, magAssist announced that it will continue to deepen its expertise in the field of life support, accelerate the globalization of its independent innovation achievements, and allow China's intelligent manufacturing to protect more lives.

- END -